Skip to main content
In stock | Targeted Therapy

Lapatinib

Oncology Type Solid Tumour
Drug Class / Mechanism EGFR / HER2 Tyrosine Kinase Inhibitor
No Image
Description

Lapatinib is classified as an EGFR / HER2 Tyrosine Kinase Inhibitor, sourced for use within our Targeted Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Targeted Therapy
Oncology Type Solid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3